drugset / Trial / NCT00403481

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

NCT00403481

Phase 4 Completed 192 enrolled Daiichi Sankyo
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.

Timeline

Start
2006-11
Primary completion
2007-11
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 12.5 mg Oral
Subject Hydrochlorothiazide Unknown 25 mg Oral
Subject Olmesartan medoxomil Unknown 20 mg Oral
Subject Olmesartan medoxomil Unknown 40 mg Oral

Indications